Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902062 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL5987924 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL7773873 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL783035 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL8499157 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL7865088 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL23070514 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL133039 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL8499165 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL169336 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | claimed |
| CN-118613126-B | Preparation method of high-quality tin-based halide perovskite film | 吉林化工学院 | 2025-02-25 | — | — | CN | claimed |
| EP-4472995-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118613126-A | Preparation method of high-quality tin-based halide perovskite film | 吉林化工学院 | 2024-09-06 | — | — | CN | claimed |
| CN-117843980-A | Ion secondary battery electrode material of organic micro-nano multi-stage super structure and application thereof | 南京工业大学 | 2024-04-09 | — | — | CN | claimed |
| CN-117603250-A | Method for preparing isocyanate from polycarbonate | 诠达化学股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| CN-113072923-B | Nano capsule gel breaker with controllable delivery and release, and preparation method and application thereof | 中国石油大学(华东) | 2023-02-17 | — | — | CN | claimed |
| US-11453738-B2 | Organic-inorganic hybrid material, fabrication process of the same and its starting material | CHANDA CHEMICAL CORP. (TW) | 2022-09-27 | — | — | US | claimed |
| EP-0387178-B2 | Process for the preparation of clavulinic acid and pharmaceutically acceptable salts from fermentation broths of Streptomyces sp. | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | claimed |
| WO-2000021515-A9 | INTRANASAL CODEINE FOR THE RAPID SUPPRESSION OF COUGH AND RAPID RELIEF OF PAIN | NEW MILLENNIUM PHARMACEUTICAL (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2000021515-A2 | INTRANASAL CODEINE FOR THE RAPID SUPPRESSION OF COUGH AND RAPID RELIEF OF PAIN | NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0387178-B1 | Process for the preparation of clavulinic acid and pharmaceutically acceptable salts from fermentation broths of Streptomyces sp. | SMITHKLINE BEECHAM PLC (GB) | 1997-01-02 | — | — | EP | claimed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0477160-A1 | Process for producing N-substituted-1-deoxynojirimycin | MONSANTO COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0336400-A2 | Developer for dry ps plates | FUJI PHOTO FILM CO., LTD. (JP) | 1989-10-11 | — | — | EP | claimed |
| EP-0164706-B1 | PHENYLALKYL AMINE BIOREGULATORS | BASF Aktiengesellschaft (DE) | 1989-04-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAOA 4209/4885HTR2A 1937/4885CYP2A6 1377/4885 |
| US-11453738-B2 | Organic-inorganic hybrid material, fabrication process of the same and its starting material | INTS9, CA4, INCENP | MAOA 424/4885HTR2A 1977/4885CYP2A6 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.